论文部分内容阅读
Objective:To evaluate the effectiveness and safety of p -elemene Injection as an adjunctive treatment for lung cancer by systematic review.Methods:We retrieved randomized controlled clinical trials related to the use of p -elemene Injection as an adjunctive treatment for lung cancer from Chinese Biomedical(CBMweb), Chinese Medical Current Content(CMCC),China National Knowledge Infrastructure(CNKI),Chinalnfo,Cochrane Central Register of Controlled Trials;MEDLINE,EMBASE,OVID and TCMLARS.We also referred to an unpublished conference proceeding titled Clinical Use and Basic:Elemene Injection.We then divided the studies into non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) subgroups by RevMan 5.1 software. Results:A total of 21 source documents(1,467 patients) matched pre-specified criteria for determining the effectiveness and safety of p -elemene Injection as an adjunctive treatment for lung cancer.Five studies involving 285 NSCLC patients reported a higher 24-month survival rate(39.09%) with the adjunctive treatment than with chemotherapy alone(26.17%;RR,1.51;95%CI,1.03 to 2.21).Four studies involving 445 patients reported that the increased probability for improved performance status for patients treated with elemene-based combinations was higher than that of patients treated with chemotherapy alone(RR,1.82;95%CI,1.45 to 2.29).The results from a subgroup analysis on 12 studies involving 974 NSCLC patients and 9 studies involving 593 patients with both SCLC and NSCLC showed that the tumor control rate for NSCLC improved more in the elemene-based combinations treatment group(78.70%) than in the chemotherapy alone control group(71.31%;RR,1.06;95% CI,1.00 to 1.12).The tumor response rate for NSCLC also improved more among patients treated with elemene- based combinations(50.71%) than among patients treated with chemotherapy alone(38.04%;RR,1.34;95%CI, 1.17 to 1.54).In addition,the main adverse reaction toβ-elemene Injection was phlebitis,but usually only to a mild degree.An Egger’s test showed no publication bias in our study(P=0.7030).Conclusions:The effectiveness of chemotherapy for the treatment of lung cancer may improve when combined withβ-elemene injection as an adjunctive treatment.The combined treatment can result in an improved quality of life and prolonged survival. However,these results require confirmation by rigorously controlled trials.
Objective: To evaluate the effectiveness and safety of p -elemene Injection as an adjunctive treatment for lung cancer by systematic review. Methods: We retrieved randomized controlled clinical trials related to the use of p -elemene Injection as an adjunctive treatment for lung cancer from Chinese Biomedical (CBMweb), Chinese Medical Current Content (CMCC), China National Knowledge Infrastructure (CNKI), Chinalnfo, Cochrane Central Register of Controlled Trials; MEDLINE, EMBASE, OVID and TCMLARS.We also refer to an unpublished conference proceeding titled Clinical Use and Basic: Elemene Injection. We then divided the studies into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) subgroups by RevMan 5.1 software. Results: A total of 21 source documents (1,467 patients) matched pre-specified criteria for determining the effectiveness and safety of p -elemene Injection as an adjunctive treatment for lung cancer. Study studies involving 285 NSCLC patients reported a higher 24-month survivor iour rate (39.09%) with the adjunctive treatment than with chemotherapy alone (26.17%; RR, 1.51; 95% CI, 1.03 to 2.21) .Four studies involving 445 patients reported that the increased probability for improved performance status for patients treated with elemene -based combinations was higher than that of patients treated with chemotherapy alone (RR, 1.82; 95% CI, 1.45 to 2.29). Results from a subgroup analysis on 12 studies involving 974 NSCLC patients and 9 studies involving 593 patients with both SCLC and NSCLC showed that the tumor control rate for NSCLC improved more in the elemene-based combination treatment group (78.70%) than in the chemotherapy alone control group (71.31%; RR, 1.06; 95% CI, 1.00 to 1.12) rate for NSCLC also improved more among patients treated with elemene-based combinations (50.71%) than among patients treated with chemotherapy alone (38.04%; RR, 1.34; 95% CI, 1.17 to 1.54) -elemene Injection was phlebitis, but usually on ly to a mild degree. Ann Egger’s test showed no publication bias in our study (P = 0.7030). Conclusions: The effectiveness of chemotherapy for the treatment of lung cancer may improve when combined with beta-elemene injection as an adjunctive treatment. The combined treatment However, these results require confirmation confirmation rigorously controlled trials.